

Harveshp Mogal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/355653/publications.pdf>

Version: 2024-02-01

52
papers

888
citations

471509

17
h-index

501196

28
g-index

52
all docs

52
docs citations

52
times ranked

1683
citing authors

#	ARTICLE	IF	CITATIONS
1	The Evolving Management of Peritoneal Surface Malignancies. <i>Current Problems in Surgery</i> , 2021, 58, 100860.	1.1	2
2	A novel preoperative risk score to optimize patient selection for performing concomitant liver resection with cytoreductive surgery/HIPEC. <i>Journal of Surgical Oncology</i> , 2021, 123, 187-195.	1.7	4
3	A novel preoperative risk score to guide patient selection for resection of soft tissue sarcoma lung metastases: An analysis from the United States Sarcoma Collaborative. <i>Journal of Surgical Oncology</i> , 2021, 124, 1477-1484.	1.7	7
4	Two-Stage Hepatectomy for Bilateral Colorectal Liver Metastases: A Multi-institutional Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 1457-1465.	1.5	17
5	Molecular and Genetic Markers in Appendiceal Mucinous Tumors: A Systematic Review. <i>Annals of Surgical Oncology</i> , 2020, 27, 85-97.	1.5	22
6	Primary Liver Cancer: An NCDB Analysis of Overall Survival and Margins After Hepatectomy. <i>Annals of Surgical Oncology</i> , 2020, 27, 1156-1163.	1.5	7
7	Readmissions After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a US HIPEC Collaborative Study. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 165-176.	1.7	26
8	Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative. <i>Annals of Surgical Oncology</i> , 2020, 27, 4980-4995.	1.5	15
9	Analysis of textbook outcomes among patients undergoing resection of retroperitoneal sarcoma: A multi-institutional analysis of the US Sarcoma Collaborative. <i>Journal of Surgical Oncology</i> , 2020, 122, 1189-1198.	1.7	19
10	High neutrophil-lymphocyte ratio is not independently associated with worse survival or recurrence in patients with extremity soft tissue sarcoma. <i>Surgery</i> , 2020, 168, 760-767.	1.9	2
11	Predictors of Non-home Discharge after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Journal of Surgical Research</i> , 2020, 255, 475-485.	1.6	5
12	The impact of HIPEC vs. EPIC for the treatment of mucinous appendiceal carcinoma: a study from the US HIPEC collaborative. <i>International Journal of Hyperthermia</i> , 2020, 37, 1182-1188.	2.5	5
13	Comparison of overall survival in gallbladder carcinoma at academic versus community cancer centers: An analysis of the National Cancer Data Base. <i>Journal of Surgical Oncology</i> , 2020, 122, 176-182.	1.7	7
14	The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPEC. <i>Annals of Surgical Oncology</i> , 2020, 27, 4894-4907.	1.5	11
15	Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 748.	2.4	22
16	Outcomes of palliative-intent surgery in retroperitoneal sarcoma—Results from the US Sarcoma Collaborative. <i>Journal of Surgical Oncology</i> , 2020, 121, 1140-1147.	1.7	7
17	Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways. <i>Journal of Surgical Oncology</i> , 2020, 122, 980-985.	1.7	10
18	Neoadjuvant radiation improves margin-negative resection rates in extremity sarcoma but not survival. <i>Journal of Surgical Oncology</i> , 2020, 121, 1249-1258.	1.7	9

#	ARTICLE	IF	CITATIONS
19	Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Not Associated with Prohibitive Complications: Results of a Multiinstitutional Retrospective Study. <i>Annals of Surgical Oncology</i> , 2020, 27, 4883-4891.	1.5	11
20	Comparison of open and closed hyperthermic intraperitoneal chemotherapy: Results from the United States hyperthermic intraperitoneal chemotherapy collaborative. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 756-767.	2.0	21
21	Implications of postoperative complications on survival after cytoreductive surgery and HIPEC: A multi-institutional analysis of the United States HIPEC Collaborative.. <i>Journal of Clinical Oncology</i> , 2020, 38, 40-40.	1.6	0
22	The intersection of age and tumor biology with postoperative outcomes in patients after cytoreductive surgery and HIPEC.. <i>Journal of Clinical Oncology</i> , 2020, 38, 184-184.	1.6	0
23	Outcomes of Elderly Patients Undergoing Curative Resection for Retroperitoneal Sarcomas: Analysis From the US Sarcoma Collaborative. <i>Journal of Surgical Research</i> , 2019, 233, 154-162.	1.6	6
24	Predictors of Disease-Free and Overall Survival in Retroperitoneal Sarcomas: A Modern 16-Year Multi-Institutional Study from the United States Sarcoma Collaboration (USSC). <i>Sarcoma</i> , 2019, 2019, 1-8.	1.3	11
25	Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative. <i>Annals of Surgical Oncology</i> , 2019, 26, 3542-3549.	1.5	19
26	The impact of unplanned excisions of truncal/extremity soft tissue sarcomas: A multi-institutional propensity score analysis from the US Sarcoma Collaborative. <i>Journal of Surgical Oncology</i> , 2019, 120, 332-339.	1.7	25
27	In Patients with Localized and Resectable Gastric Cancer, What is the Optimal Extent of Lymph Node Dissection—D1 Versus D2 Versus D3?. <i>Annals of Surgical Oncology</i> , 2019, 26, 2912-2932.	1.5	20
28	Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 2234-2240.	1.5	16
29	RAS Mutation Status Confers Prognostic Relevance in Patients Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer. <i>Journal of Surgical Research</i> , 2019, 240, 130-135.	1.6	13
30	Effect of Donor Race-Matching on Overall Survival for African-American Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma. <i>Journal of the American College of Surgeons</i> , 2019, 228, 245-254.	0.5	8
31	Elective Regional Therapy Treatment for Hepatic Adenoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 125-130.	1.5	10
32	Minimally invasive hepatectomy conversions: an analysis of risk factors and outcomes. <i>Hpb</i> , 2018, 20, 132-139.	0.3	23
33	Gallbladder carcinoma: An analysis of the national cancer data base to examine hispanic influence. <i>Journal of Surgical Oncology</i> , 2018, 117, 1664-1671.	1.7	4
34	Overall survival after resection of retroperitoneal sarcoma at academic cancer centers versus community cancer centers: An analysis of the National Cancer Data Base. <i>Surgery</i> , 2018, 163, 318-323.	1.9	29
35	The effect of prior upper abdominal surgery on outcomes after liver transplantation for hepatocellular carcinoma: An analysis of the database of the organ procurement transplant network. <i>Surgery</i> , 2018, 163, 1028-1034.	1.9	8
36	Modified Frailty Index Predicts Morbidity and Mortality After Pancreaticoduodenectomy. <i>Annals of Surgical Oncology</i> , 2017, 24, 1714-1721.	1.5	117

#	ARTICLE	IF	CITATIONS
37	External radiation or ablation for solitary hepatocellular carcinoma: A survival analysis of the SEER database. <i>Journal of Surgical Oncology</i> , 2017, 116, 307-312.	1.7	21
38	The Effects of Travel Burden on Outcomes After Resection of Extrahepatic Biliary Malignancies: Results from the US Extrahepatic Biliary Consortium. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 2016-2024.	1.7	20
39	The prognostic utility of baseline alpha-fetoprotein for hepatocellular carcinoma patients. <i>Journal of Surgical Oncology</i> , 2017, 116, 831-840.	1.7	27
40	Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. <i>Hpb</i> , 2017, 19, 659-666.	0.3	84
41	Two-stage hepatectomy for colorectal liver metastases: A multi-institutional retrospective review.. <i>Journal of Clinical Oncology</i> , 2017, 35, 351-351.	1.6	0
42	Actual 5-year survivors following resection of hilar cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 352-352.	1.6	10
43	Does hepatectomy approach influence transfusion? An analysis of the National Surgical Quality Improvement Program database.. <i>Journal of Clinical Oncology</i> , 2017, 35, 447-447.	1.6	0
44	Minimally invasive hepatectomy conversions: An analysis of outcomes.. <i>Journal of Clinical Oncology</i> , 2017, 35, 430-430.	1.6	0
45	Intracystic papillary carcinoma of the breast: A SEER database analysis of implications for therapy. <i>Breast</i> , 2016, 27, 87-92.	2.2	26
46	Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 129-42.	1.4	17
47	Curative resection for hilar cholangiocarcinoma: Does adjuvant therapy impact overall survival? A multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium.. <i>Journal of Clinical Oncology</i> , 2016, 34, 388-388.	1.6	0
48	A novel pathology-based preoperative risk score to predict distant and locoregional residual disease and survival for incidentally discovered gallbladder cancer: A 10-institution study from the US Extrahepatic Biliary Malignancy Consortium.. <i>Journal of Clinical Oncology</i> , 2016, 34, 202-202.	1.6	0
49	Optimal prognostic lymph node staging system for gallbladder adenocarcinoma: A multi-institutional study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 364-364.	1.6	0
50	Clopidogrel use as a risk factor for poor outcomes after kidney transplantation. <i>American Journal of Surgery</i> , 2014, 208, 556-562.	1.8	6
51	Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies. <i>Experimental Hematology and Oncology</i> , 2013, 2, 31.	5.0	79
52	Nodal Status, Number of Lymph Nodes Examined, and Lymph Node Ratio: What Defines Prognosis after Resection of Colon Adenocarcinoma?. <i>Journal of the American College of Surgeons</i> , 2013, 217, 1090-1100.	0.5	60